Abstract:
Methicillin-resistant S. aureus (MRSA) remains the leading cause of bacterial infections worldwide with a dwindling repertoire of effective antimicrobials active against it. This review aims to provide an update on novel anti-MRSA molecules currently under pre-clinical and clinical development with emphasis on their mechanism of action. This review is limited to molecules that target the pathogen directly and does not detail immunomodulatory anti-infectives.
